2,5-Dimethyl Celecoxib is primarily investigated for its potential therapeutic applications, particularly in the field of cancer research. It has shown promise as a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme associated with inflammation and tumor growth. By targeting COX-2, it may help reduce inflammation and inhibit the progression of certain cancers, such as colorectal and breast cancer. Additionally, studies suggest its role in inducing apoptosis (programmed cell death) in cancer cells, making it a candidate for further development in oncology treatments. Research is ongoing to explore its efficacy and safety in preclinical models.